A unique sodium hyaluronate system designed for deep skin hydration
Recent developments in phage-assisted continuous evolution (PACE) 34 have substantially expanded our ability to generate bespoke proteases 23,35,36 , yielding evolved BoNT proteases that selectively cleave target proteins other than their native SNARE substrates 23
(NASDAQ: ALT) announced that pemvidutide received FDA Breakthrough Therapy designation for the treatment of MASH, further advancing development of the companys GLP-1/glucagon dual receptor agonist platform
Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ